| 胡 斌,张龙富,余荣环,茅俊杰,管 超.布地奈德福莫特罗粉吸入治疗肺癌合并慢阻肺患者的临床疗效及对患者生活质量的影响[J].,2017,17(29):5686-5689 |
| 布地奈德福莫特罗粉吸入治疗肺癌合并慢阻肺患者的临床疗效及对患者生活质量的影响 |
| Clinical Efficacy of Inhaled Therapy with Symbicort Turbulaler in the Treatment of Patients with Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease and the Effect on the Quality of Life |
| 投稿时间：2017-05-06 修订日期：2017-05-30 |
| DOI：10.13241/j.cnki.pmb.2017.29.019 |
| 中文关键词: 肺癌 慢性阻塞性肺疾病 布地奈德福莫特罗粉 生活质量 吸入性药物治疗 |
| 英文关键词: Lung cancer Chronic obstructive pulmonary disease Bbu Di Ned Fumo Tero Fen Quality of life Inhaled therapy |
| 基金项目:中国科学院上海临床研究中心基金项目(BRC2012002) |
|
| 摘要点击次数: 168 |
| 全文下载次数: 99 |
| 中文摘要: |
| 摘要 目的：评价布地奈德福莫特罗粉吸入治疗肺癌合并慢性阻塞性肺气肿(COPD)患者的临床疗效及对患者生活质量的影响。方法：选择2015年1月~2016年12月我院收治的肺癌合并COPD患者68例，按照随机数字表法分为治疗组和对照组，每组34例。对照组给予常规对症治疗，治疗组在对照组的基础上给予布地奈德福莫特罗粉吸入剂治疗，2次/天，规律治疗3个月。比较两组患者治疗前后用力肺活量占预测值的百分比(FVC%)、第一秒用力呼气量占预测值的百分比(FEV1%)水平、COPD评估测试及圣乔治呼吸问卷(SGRQ)评分的变化。结果：治疗后，两组FVC%、FEV1%均较治疗前明显升高，且治疗组显著高于对照组(P<0.05)；两组CAT评分、症状评分、活动评分及总评分均较治疗前明显降低，且治疗组显著低于对照组(P<0.05)。两组并发症发生率无显著性差异(P>0.05)。结论：布地奈德福莫特罗粉吸入治疗肺癌合并COPD可有效改善患者的肺功能和生活质量。 |
| 英文摘要: |
| ABSTRACT Objective: To evaluate the clinical efficacy of inhaled therapy with symbicort turbulaler in the treatment of patients with lung cancer complicated with chronic obstructive pulmonary disease(COPD) and the effect on the quality of life(QOL). Methods: 68 patients with COPD and lung cancer who were treated in our hospital from January 2015 to December 2016 were divided into 2 groups according to the random number table with 34 cases in each group. The control Group was given conventional symptomatic treatment, while the treatment group was additionally given budesonide and foradil powder for inhalation, 2 times per day for 3 months. The changes of percentage of forced vital capacity (FVC%), percentage of forced expiratory volume in 1 second(FEV1%), COPD Assessment Test (CAT), St Georges respiratory questionnaire(SGRQ) in two groups were compared before and after treatment. Results: After treat- ment, the levels of FVC%, FEV1% in both groups were significantly improved, and which were significantly better than those of the control group (P<0.05). The CAT score, symptom scores, activity score and total score in both group were significantly reduced com- pared with those before treatment, and which were significantly lower in the treatment group than those of the control group (P<0.05). There was no significant difference in the occurrence of complications between two groups(P>0.05). Conclusion: Inhaled therapy with symbicort turbulaler could effectively improve the lung function and QOL of COPD patients complicated with lung cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
